Press Releases
Daman enters collaboration to provide further insights into patients' lives in the effort to deliver better outcomes for people with psoriatic arthritis (PsA)
Copenhagen - 25 May 2022 - Life Science Newswire - Daman is excited to announce that they have signed an agreement with Janssen Pharmaceutica NV (Janssen) to deliver a digital health tool (mobile application) to be used in a clinical study among people living with psoriatic arthritis. Benefitting from the HealthBuddy platform, the agreement involves developing a digital health tool for use in a clinical trial, enabling Janssen to gain new insights into how patients’ everyday lives are affected by their disease.
Affecting more than 5M patients in Europe and 37.5M worldwide, Psoriatic Arthritis (PsA) imposes a high burden on individuals, societies, and the healthcare sector. The collection and utilisation of Patient Reported Outcomes (PROs) is expected to enable the transition towards more holistic care, aiming to achieve a higher quality of life for patients.
With the HealthBuddy platform—using the validated concept of the RheumaBuddy app (already used by 20,000+ Rheumatoid Arthritis patients in Europe)—Janssen will be able to not only provide patients with a valuable tool, but also obtain longitudinal data-driven insights on the everyday lives of patients enrolled in their clinical trial.
“We are excited to work with a forward-looking pharmaceutical company like Janssen on implementing an innovative digital health technology in their clinical trials. This really shows the meaning of their vision of being patient-centric,” says Andreas Dam, CEO at Daman. He continues: “Studies have shown that PROs deliver better ecological validity when filled by patients outside the clinic. Here, digital health tools are the obvious choice”.
“Despite advances in treatment, there remains several unmet needs among people living with psoriatic arthritis. We are happy to see many companies in pharmaceutical industry and digital health partner up to co-create powerful solutions,” says Jan Koren, President at EUROPSO, the federation of psoriasis patients’ associations in Europe, who has taken part in the co-creation process.
About RheumaBuddy, HealthBuddy and Daman
Launched in 2014 and used by 20,000+ patients in 35 countries, RheumaBuddy is a market leader mobile application for patients living with the chronic disease Rheumatoid Arthritis (RA). The digital health app is developing into the next-generation context-aware algorithm-driven app, designed to help patients self-manage their disease. RheumaBuddy will become a platform that benefits all stakeholders in the rheumatology care eco-system: patients, healthcare professionals, patient organizations, payers, and pharmaceutical companies by enabling a holistic care approach, and thereby supporting the importance of co-creation to generate real patient value and to improve quality of life.
RheumaBuddy is built on the HealthBuddy platform, currently applied within several disease areas at the European and global level and serving thousands of people with chronic diseases, including cancer, psoriasis, HIV, heart failure and more.
Daman, a digital healthcare partner based in Denmark, enables innovative teams develop life-changing solutions for people living with chronic diseases, who deserve to enjoy the highest achievable quality of life. This is made possible by using a co-creation methodology to develop top-grade and patient-centric digital health solutions.
